AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
89.82
-1.46 (-1.60%)
At close: Dec 9, 2025, 4:00 PM EST
91.71
+1.89 (2.10%)
Pre-market: Dec 10, 2025, 8:45 AM EST
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
4.83
Revenue / Employee
$625,694
Employees
92,900
Market Cap
280.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
AZN News
- 2 days ago - BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 - Accesswire
- 5 days ago - Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement - Business Wire
- 6 days ago - AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - Business Wire
- 7 days ago - Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension - Business Wire
- 13 days ago - Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies - CNBC
- 15 days ago - AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows - Benzinga
- 16 days ago - Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology - PRNewsWire
- 18 days ago - Why AstraZeneca Stock Bumped Higher Today - The Motley Fool